Uncategorized
Novaliq begins patient enrollment for phase 2 trial of CyclASol for dry eye disease
Novaliq has started to enroll patients in a phase 2 trial of CyclASol to treat dry eye disease, the company announced in a press release. The randomized, double-masked, placebo-controlled multicenter phase 2 trial will evaluate the safety, efficacy and tolerability of topical CyclASol (cyclosporine in semifluorinated alkanes) for the treatment of patients with moderate to severe dry eye disease.